NGS Data Analysis Market Outlook (2024 to 2034)
The global NGS data analysis market size is forecasted to reach a value of US$ 2.03 billion by the end of 2034, up from US$ 746.9 million in 2024. This increase equals to 10.5% CAGR for the next ten years (2024 to 2034). Rigorous technological advancements in the field of data generation, integration, storage, and access as well as cloud computing solutions aid in overcoming data-handling constraints, which requires evaluating enormous amounts of high-throughput sequence data.
In comparison to early practices of data storage in the form of physical written files cloud storage has been a boon to the sequence analysis industry. Next-generation sequencing (NGS) has greatly aided in the investigation of epigenetics and genomic patterns linked with several biological processes. The inevitable need for NGS data analysis in research and development in almost every domain is contributing to market growth.
Substantial rise in the demand for sequence analysis tools for precise interpretation of short or long, single or multiple, genomic, protein, or amino acid sequences has boosted the use of NGS data analysis tools. Next-generation sequencing technology enables in-depth analysis of biological systems by researchers because of its unmatched throughput, speed, and scalability.
Compared to what is offered by traditional DNA sequencing techniques, the complexity of genomic research demands a higher level of comprehension. Next-generation sequencing has become a regular research methodology to address these expectations.
| Report Attributes |
Details |
| NGS Data Analysis Market Size (2024E) |
US$ 746.9 Million |
| Projected Market Value (2034F) |
US$ 2.03 Billion |
| Global Market Growth Rate (2024 to 2034) |
10.5% CAGR |
| China Market Value (2024E) |
US$ 56 Million |
| Canada Market Growth Rate (2024 to 2034) |
14.2% CAGR |
| North America Market Share (2024E) |
36% |
| East Asia Market Value (2034F) |
US$ 381.7 Million |
| Key Companies Profiled |
Roche; Illumina; Genestack; Edge Biosystems; DNAnexus; Biomatters Ltd.; ABM Inc.; Agilent Technologies |
What are the Key NGS Data Analysis Market Trends?
“Rising Need for Precise Sequencing Interpretation in Personalized Medicine and Genomic Research”
Advancements in next-generation sequencing (NGS) technologies and their expanding application in clinical diagnosis, genomic research, and personalized medicine for a variety of diseases are augmenting the demand for precise and speedy sequencing interpretation tools and algorithms that can accelerate data analysis.
NGS protocols have been extensively used for oncology precise medicine, particularly for breast and lung tumors. Genetic research such as the detection of somatic driver mutations, germline mutations, resistance mutations, tumor genotyping, and quantification of mutational load can be carried out with the advent of improved algorithms and software in next-generation sequencing. Additionally, these developments have laid a new foundation for treating cancer-related illnesses.
What Challenges are NGS Analysis Solution Providers Encountering?
“High Infrastructural Costs and Inadequate Number of Skilled Professionals”
Advent of technology comes with financial irregularities. Though NGS data analysis has solved much of the research and development problems, there are many factors restraining market growth. The high setup costs associated with the software and algorithms are projected to suppress market growth in the near future.
The cost of premium next-generation sequencing devices, including installation, maintenance, reagents, and data analysis, can exceed millions of dollars. Most market participants favor sequencing as a service rather than investing in internal research. Moreover, many healthcare professionals are unaware of technological advancements. The market encounters challenging constraints due to a shortage of skilled technology operators among end-users.
Country-wise Insights
Fact.MR, a market research and competitive intelligence provider, through its newly published analysis, asserts that North America is projected to hold 35.3% of the global NGS data analysis market share by 2034.
Key manufacturers of NGS data analysis have broadened their operations to various regions worldwide such as Southeast Asia, Central and South America, and Australia. This expansion allows them to effectively cater to the growing global demand and diversify their supply sources.
What is Driving Market Growth in the United States?
“Decreasing Cost of Sequencing Leading to More Complex Bioinformatics Pipelines”
| Attribute |
United States |
| Market Value (2024E) |
US$ 233.8 Million |
| Growth Rate (2024 to 2034) |
10.8% CAGR |
| Projected Value (2034F) |
US$ 651.9 Million |
Growth of the market in the United States is being driven by the increasing use of NGS in clinical diagnosis and personalized medicine. As NGS technologies become advanced, they are being used more frequently in the medical field, leading to a higher demand for data analysis. Falling costs of sequencing are allowing for larger sequencing projects, which in turn boosts the need for complex bioinformatics pipelines.
Market growth is also fueled by continuous technological advancements and the increasing application of NGS in various fields. Partnerships between companies such as the one between SOPHiA GENETICS and QIAGEN N.V. are enhancing the efficiency of NGS data analysis, thus driving market growth.
The COVID-19 pandemic highlighted the importance of genomic sequencing in response and surveillance. These tools are enabling researchers to analyze large volumes of genomic data quickly and accurately, which leads to the efficient identification of viral variants. The positive influence of the COVID-19 pandemic on the industry has also contributed to NGS data analysis market growth.
Why is Adoption of NGS Data Analysis Solutions Rising in China?
“Surge in Number of Large-scale Sequencing Projects”
| Attribute |
China |
| Market Value (2024E) |
US$ 56 Million |
| Growth Rate (2024 to 2034) |
15.5% CAGR |
| Projected Value (2034F) |
US$ 237.3 Million |
Increasing adoption of NGS technologies in clinical diagnosis, personalized medicine, and genomic research is a significant driver. The growth of large-scale sequencing projects driven by the falling costs of sequencing is also increasing the need for sophisticated bioinformatics pipelines.
Ongoing technological advancements and the expanding applications of NGS across various fields are fueling market growth. Partnerships between companies are also playing a crucial role in enhancing NGS data analysis capabilities.
Category-wise Insights
Why Does Whole-Genome Sequencing Account for Increased Demand?
“Advancements in Genomic Research and Growing Preference for NGS Technologies”
| Attribute |
Whole-Genome Sequencing |
| Segment Value (2024E) |
US$ 213.6 Million |
| Growth Rate (2024 to 2034) |
11.6% CAGR |
| Projected Value (2034F) |
US$ 642.8 Million |
Adoption of whole-genome sequencing service type is driven by advancements in genomic research. The growing application of NGS in diverse fields such as oncology, infectious disease research, personalized medicine, agriculture, and forensics is driving market growth. The unparalleled ability of NGS to rapidly sequence DNA and RNA with high accuracy and throughput has revolutionized genomic studies.
There is a growing need for robust data analysis tools capable of handling vast volumes of sequencing data, deciphering intricate genomic patterns, and facilitating actionable interpretations.
Technological advancements and innovations in NGS data analysis platforms are reshaping the landscape of genomic research and clinical diagnostics. Companies are increasingly focusing on developing sophisticated algorithms, machine learning techniques, and cloud-based solutions for streamlined data processing, enhanced accuracy, and improved scalability. Collaborations between bioinformatics firms, academic institutions, and healthcare providers are supporting the development of integrated NGS data analysis pipelines.
As the market continues to evolve, stakeholders must stay aware of emerging NGS data analysis market trends and invest in cutting-edge solutions to harness the full potential of NGS technologies and drive transformative advancements in precision medicine. Moreover, the reduced cost of whole-genome sequencing technologies has made it more accessible to researchers, clinicians, and patients alike.
What is the Role of NGS Data Analysis in Academic Research?
“NGS Enabling Analysis of Vast Volumes of Sequencing Data and Intricsate Genomic Patterns”
| Attribute |
Academic Research Institutes |
| Segment Value (2024E) |
US$ 234.6 Million |
| Growth Rate (2024 to 2034) |
11.5% CAGR |
| Projected Value (2034F) |
US$ 694.1 Million |
In 2024, the academic research segment is estimated to hold a market share of 31.4%. This dominance can be attributed to an increase in the acceptance of NGS data analysis workflows in educational institutions. By 2034, academic and research institutes are projected to hold a market share of 34.2%, due to the increasing adoption of NGS platforms.
NGS technologies are extensively used in academic research due to the need for robust data analysis tools that are capable of handling vast volumes of sequencing data. Understanding intricate genomic patterns and facilitating actionable interpretations are the primary purposes of these tools. As genomic research continues to evolve, academic institutions are at the forefront of adopting advanced NGS data analysis tools to drive scientific discovery and innovation.
Competitive Landscape
Market growth is being driven by several factors, including evolving consumer preferences, technological advancements, and global economic conditions. Key players in the NGS data analysis market are Roche, Illumina, Genestack, Edge Biosystems, DNAnexus, Biomatters Ltd, ABM Inc., and Agilent Technologies.
- In 2023, Illumina Inc., a global pioneer in DNA sequencing and array-based technologies, launched a new product called Connected Insights. This innovative cloud-based software is designed to facilitate the tertiary analysis of clinical data derived from next-generation sequencing (NGS).
